Literature DB >> 25735977

EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.

Fuchun Guo1, Xiaoke Liu2, Qin Qing3, Yaxiong Sang4, Chengjun Feng5, Xiaoyu Li6, Li Jiang7, Pei Su8, Yongsheng Wang9.   

Abstract

The echinoderm microtubule-associated protein-like 4(EML4)--anaplastic lymphoma kinase (ALK) fusion gene has been identified as a driver mutation in non-small-cell lung cancer (NSCLC). However, the role of EML4-ALK in malignant transformation is not entirely clear. Here, for the first time, we showed that H1299 NSCLC cells stably expressing EML4-ALK acquire EMT phenotype, associated with enhanced invasive migration and increased expression of EMT-inducing transcription factors. H1299-EML4-ALK cells also displayed cancer stem cell-like properties with a concomitant up-regulation of CD133 and enhanced ability of mammospheres formation. Moreover, we found that inhibition of ERK1/2 reversed EMT induced by EML4-ALK in H1299 cells. Taken together, these results suggested that EML4-ALK induced ERK activation is mechanistically associated with EMT phenotype. Thus, inhibition of ERK signaling pathway could be a potential strategy in treatment of NSCLC patients with EML4-ALK translocation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cell; EML4-ALK; EMT; ERK1/2

Mesh:

Substances:

Year:  2015        PMID: 25735977     DOI: 10.1016/j.bbrc.2015.02.114

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma.

Authors:  Sen Yang; Li Yang; Yufeng Wu; Cuicui Zhang; Shuai Wang; Nan Ma; Li Wang; Qiming Wang
Journal:  Ann Transl Med       Date:  2020-10

3.  Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.

Authors:  Gonzalo Recondo; Laura Mezquita; Francesco Facchinetti; David Planchard; Anas Gazzah; Ludovic Bigot; Ahsan Z Rizvi; Rosa L Frias; Jean Paul Thiery; Jean-Yves Scoazec; Tony Sourisseau; Karen Howarth; Olivier Deas; Dariia Samofalova; Justine Galissant; Pauline Tesson; Floriane Braye; Charles Naltet; Pernelle Lavaud; Linda Mahjoubi; Aurélie Abou Lovergne; Gilles Vassal; Rastilav Bahleda; Antoine Hollebecque; Claudio Nicotra; Maud Ngo-Camus; Stefan Michiels; Ludovic Lacroix; Catherine Richon; Nathalie Auger; Thierry De Baere; Lambros Tselikas; Eric Solary; Eric Angevin; Alexander M Eggermont; Fabrice Andre; Christophe Massard; Ken A Olaussen; Jean-Charles Soria; Benjamin Besse; Luc Friboulet
Journal:  Clin Cancer Res       Date:  2019-10-04       Impact factor: 12.531

4.  Inactivation of the Ras/MAPK/PPARγ signaling axis alleviates diabetic mellitus-induced erectile dysfunction through suppression of corpus cavernosal endothelial cell apoptosis by inhibiting HMGCS2 expression.

Authors:  Zhuo Zhang; Hai-Yan Zhang; Ying Zhang; Hai Li
Journal:  Endocrine       Date:  2018-11-20       Impact factor: 3.633

5.  Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma.

Authors:  H Inoue; M Hashimura; M Akiya; R Chiba; M Saegusa
Journal:  Mol Cancer       Date:  2017-02-14       Impact factor: 27.401

Review 6.  Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance.

Authors:  Etienne Giroux-Leprieur; Adrien Costantini; Vivianne W Ding; Biao He
Journal:  Int J Mol Sci       Date:  2018-09-19       Impact factor: 5.923

Review 7.  Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Authors:  Sara Verdura; Elisabet Cuyàs; Verónica Ruiz-Torres; Vicente Micol; Jorge Joven; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

8.  Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.

Authors:  Claudia Voena; Lydia M Varesio; Liye Zhang; Matteo Menotti; Teresa Poggio; Elena Panizza; Qi Wang; Valerio G Minero; Sharmila Fagoonee; Mara Compagno; Fiorella Altruda; Stefano Monti; Roberto Chiarle
Journal:  Oncotarget       Date:  2016-05-31

9.  SH2B1 promotes epithelial-mesenchymal transition through the IRS1/β-catenin signaling axis in lung adenocarcinoma.

Authors:  Shaoqiang Wang; Yuanda Cheng; Yang Gao; Zhiwei He; Wolong Zhou; Ruimin Chang; Zhenzi Peng; Yingying Zheng; Chaojun Duan; Chunfang Zhang
Journal:  Mol Carcinog       Date:  2018-02-20       Impact factor: 4.784

10.  lincROR influences the stemness and crizotinib resistance in EML-ALK+ non-small-cell lung cancer cells.

Authors:  Yonghua Yang; Jingyu Huang; Nianlin Xie; Hu Huang; Shaogan Xu; Jun Cai; Shuai Qi
Journal:  Onco Targets Ther       Date:  2018-06-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.